Latest Breaking News On - Laurie sehn md - Page 1 : comparemela.com

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

British columbiaUnited statesUnited kingdomLaurieh sehnInternational conference on malignant lymphomaBc cancer centre for lymphoidUniversity of british columbiaAmerican society for transplantationInternational conferenceLymphoid cancerAmerican societyCellular therapyAnn arborFollicular lymphomaFixed durationComplete response